Ivacaftor (benzenesulfonate) Catalog No.:M9558-2 Leflunomide prevents the expansion of

Leflunomide prevents the expansion of activated and autoimmune lymphocytes by interfering with the cell cycle progression due to inadequate production of rUMP and utilizing mechanisms involving p53

CAS Number: 29767-20-2

4 nM (hNK-3-CHO binding Ki) Target: NK3 receptorin vitro: In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca2+ mobilization in CHO cells stably expressing the hNK-3 receptor)

2119/molmed

Ivacaftor (benzenesulfonate) Catalog No.:M9558-2 Leflunomide prevents the expansion ofVX 770, is a drug used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 45% cases of cystic fibrosis, and is included in a combination drug, lumacaftor ivacaftor, which is used to treat people with cystic fibrosis who have the F508del mutation in CFTR. Ivacaftor is a "potentiator" of CFTR, meaning it increases the probability that the defective channel